secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001193125-25-307541
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression
--------------------------------------------------------------------------------

- BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.
- 90-98% suppression of IL-1β at Day 14; doses ≥60 mg exceeded IC90 in CSF, demonstrating high brain penetration.
- Phase 1 expanded to MAD cohorts in obese participants with elevated hsCRP; data expected 1H26.
- Phase 2a proof-of-concept planned for 1H26 (100 patients, 12 weeks, primary endpoint % hsCRP change); data readout 2H26.
- Pharmacokinetics support once-daily oral dosing; dose proportionality observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/0001193125-25-307541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/bioa-20251204.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-307541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer